Evogliptin Tartrate
|
|
- CAS号:
- 1222102-51-3
- 英文名:
- Evogliptin Tartrate
- 英文别名:
- DA-1229 tartrate;Evogliptin Tartrate
- 中文名:
- Evogliptin Tartrate
- 中文别名:
- 化合物 T11248
- CBNumber:
- CB15984681
- 分子式:
- C19H26F3N3O3 · (C4H6O6)
- 分子量:
- 551.52
- MOL File:
- 1222102-51-3.mol
|
|
|
Evogliptin Tartrate化学性质
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO: 100 mg/mL (181.32 mM)
-
|
Evogliptin Tartrate性质、用途与生产工艺
Evogliptin tartrate 是一种高效、口服有效、选择性的 DPP-4 抑制剂,具有抗糖尿病活性。Evogliptin tartrate 可用于靶向动脉炎症和动脉粥样硬化的研究。
Evogliptin tartrate significantly inhibits the TNF-α-mediated induction of ICAM-1 and VCAM-1 expression in a concentration-dependent manner (IC
50
= 0.30 and 0.25 μM, respectively).
Evogliptin tartrate inhibits the TNF-α-mediated transcriptional activation of ICAM-1 and VCAM-1.
Evogliptin tartrate inhibits inflammatory responses via suppression of adhesion molecules induced by TNF-α. And TNF-α-mediated activation of NF-κB is ameliorated by evogliptin via the interaction of NF-κB with SIRT1.
Cell Viability Assay
Cell Line:
|
Endothelial cells
|
Concentration:
|
0.1 μM, 0.3 μM, 1 μM, 3 μM
|
Incubation Time:
|
12 hours
|
Result:
|
Inhibits TNF-α-mediated (10 ng/ml) expression of adhesion molecules.
|
Evogliptin tartrate (37.5-150 mg/kg; p.o.; daily; for 12 weeks) reduces the high-fat diet-induced atherosclerotic plaque area in the ApoE
−/−
mouse model.
Evogliptin tartrate inhibits the formation of atherosclerotic lesions by reducing vasoinflammation and increases plaque stability.
Animal Model:
|
ApoE
−/−
mice
|
Dosage:
|
37.5 mg/kg, 75 mg/kg, 150 mg/kg
|
Administration:
|
Oral administration; daily; for 12 weeks
|
Result:
|
Inhibit the development of atherosclerosis.
|
Evogliptin Tartrate
上下游产品信息
上游原料
下游产品
更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
---|
2024/04/30 | HY-117985B | Evogliptin tartrate | | 1 mg | 1590元 |
2024/04/30 | HY-117985B | Evogliptin Tartrate Evogliptin tartrate | 1222102-51-3 | 5mg | 3500元 |
1222102-51-3, Evogliptin Tartrate 相关搜索:
- 抑制剂
- 化合物 T11248
- 1222102-51-3
- DA-1229 tartrate
- Evogliptin Tartrate